omniture

Tianyin Pharmaceutical to Present at Roth Third Annual China Discovery Tourin Beijing on May 20, 2008 at 12:40 p.m. Beijing Time

2008-05-13 02:30 1668

CHENGDU, China, May 13 /Xinhua-PRNewswire/ -- Tianyin Pharmaceutical, Co., Inc., (OTC Bulletin Board: TYNP), a manufacturer and supplier of modernized traditional Chinese medicine ("TCM") based in Chengdu, China, today announced that the Company will present at Roth Third Annual China Discovery Tour on Tuesday, May 20, 2008 at 12:40 p.m. Beijing time. The Conference will be held at the Regent Hotel in Beijing, China.

Dr. Guoqing, Jiang, Tianyin’s Chairman and CEO, Mr. Allen Tang, assistant to the CEO, will be representing Tianyin Pharmaceutical at the conference and will be available for one-on-one meetings with analysts and investors throughout the day.

Management will discuss the Company’s current product portfolio, development pipeline, research and development platform, recent financial highlights and its long-term growth strategy.

Participation is by invitation and registration is mandatory. For more information on the conference contact your Roth representative or visit http://www.roth.com .

About Roth China Discovery Tour

The 3rd Annual China Discovery Tour will feature more than 70 companies in 7 cities throughout China, combining factory visits with management presentations in a mini conference format. This event is another chapter in Roth’s growing commitment to China. Over the past two years Roth has taken investors on more than 60 company visits in mainland China and hosted close to 200 China company presentations at its conferences. For more information about this invite only event, please contact conference@roth.com.

About Tianyin Pharmaceuticals

Tianyin is a manufacturer and supplier of modernized Traditional Chinese Medicine ("TCM") in China. It was established in 1994 and acquired by the current management team in August 2003. It has a comprehensive product portfolio of 34 modernized TCMs in the market, 22 of which are listed in the highly selective National Medicine Catalog of the National Medical Insurance Program. Tianyin owns and operates two GMP manufacturing facilities and an R&D platform supported by leading Chinese academic institutions. The Company has a pipeline of 51 pharmaceutical products pending approval. Tianyin has an extensive nationwide distribution network throughout China with a sales force of 523 salespeople. Tianyin is headquartered in Chengdu, Sichuan Province with two manufacturing facilities and a total of 869 employees. Tianyin achieved revenue of $20.4 million and net income of $3.95 million in FY2007 ending June 30, 2007.

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company’s filings with the Securities and Exchange Commission.

Source: Tianyin Pharmaceutical, Co., Inc.
Related Stocks:
NYSE:TPI
collection